載入...
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
BACKGROUND: Optimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy. PATIENTS AND METHODS: Patients with bone metastases from breast or castration-resistant prostate cancer (CRPC), w...
Na minha lista:
| 發表在: | Eur J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
The Author(s). Published by Elsevier Ltd.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7532126/ https://ncbi.nlm.nih.gov/pubmed/33023785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.08.019 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|